CoChat

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

Open access
Koeppen, Hartmut, Yu, Wei, Zha, Jiping, Pandita, Ajay, Penuel, Elicia, Rangell, Linda, Raja, Rajiv, Mohan, Sankar, Patel, Rajesh, Desai, Rupal, Fu, Ling, Do, An, Parab, Vaishali, Xia, Xiaoling, Januario, Tom, Louie, Sharianne G., Filvaroff, Ellen, Shames, David S., Wistuba, Ignacio, Lipkind, Marina, Huang, Jenny, Lazarov, Mirella, Ramakrishnan, Vanitha, Amler, Lukas, Phan, See-Chun, Patel, Premal, Peterson, Amy, Yauch, Robert L. · 2014 · Clinical Cancer Research
Cited by 136

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Purpose: In a recent phase II study of onartuzumab (MetMAb), patients whose non–small cell lung cancer (NSCLC) tissue scored as positive for MET protein by immunohistochemistry (IHC) experienced a significant benefit with onartuzumab plus erlotinib (O+E) versus erlotinib. We describe development and validation of a standardized MET IHC assay and, retrospectively, evaluate multiple biomarkers as predictors of patient benefit. Experimental Design: Biomarkers related to MET and/or EGF receptor (EGFR) signaling were measured by IHC, FISH, quantitative reverse transcription PCR, mutation detection techniques, and ELISA. Results: A positive correlation between IHC, Western blotting, and MET mRNA expression was observed in NSCLC cell lines/tissues. An IHC scoring system of MET expression taking proportional and intensity-based thresholds into consideration was applied in an analysis of the phase II study and resulted in the best differentiation of outcomes. Further analyses revealed a nonsignificant overall survival (OS) improvement with O+E in patients with high MET copy number (mean ≥5 copies/cell by FISH); however, benefit was maintained in “MET IHC-positive”/MET FISH-negative patients (HR, 0.37; P = 0.01). MET, EGFR, amphiregulin, epiregulin, or HGF mRNA expression did not predict a significant benefit with onartuzumab; a nonsignificant OS improvement was observed in patients with high tumor MET mRNA levels (HR, 0.59; P = 0.23). Patients with low baseline plasma hepatocyte growth factor (HGF) exhibited an HR for OS of 0.519 (P = 0.09) in favor of onartuzumab treatment. Conclusions: MET IHC remains the most robust predictor of OS and progression-free survival benefit from O+E relative to all examined exploratory markers. Clin Cancer Res; 20(17); 4488–98. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-13-1836

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 136

Metadata

Authors
Koeppen, H., Yu, W., Zha, J., Pandita, A., Penuel, E., Rangell, L., Raja, R., Mohan, S., Patel, R., Desai, R., Fu, L., Do, A., Parab, V., Xia, X., Januario, T., Louie, S. G., Filvaroff, E., Shames, D. S., Wistuba, I., Lipkind, M., Huang, J., Lazarov, M., Ramakrishnan, V., Amler, L., Phan, S.-C., Patel, P., Peterson, A., & Yauch, R. L.
Venue
Clinical Cancer Research
Published
2014-09-01
Volume
20
Issue
17
Pages
4488-4498
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2146137201
Cited by
136
References
4
FWCI
17.69
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-1836
The paper
Koeppen, H., Yu, W., Zha, J., Pandita, A., Penuel, E., Rangell, L., Raja, R., Mohan, S., Patel, R., Desai, R., Fu, L., Do, A., Parab, V., Xia, X., Januario, T., Louie, S. G., Filvaroff, E., Shames, D. S., Wistuba, I., . . . Yauch, R. L. (2014). Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-1836

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.